Immune thrombocytopenia (ITP) trials in China

In China 67 Also abroad 118

67 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Early phase 1Taking people
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
20
Run by
Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843
Phase 1/2Taking people
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Where
Guangzhou, Jinan, Tianjin, Wuhan
Age
18 years to 64 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00
Phase 3Taking people
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
171 worldwide
Run by
Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00
Phase 3Taking people
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
150 worldwide
Run by
Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00
No phaseNot yet taking people in China
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Where
Nanchang
Age
18 years to 65 years
People
24
Run by
Nanjing Miracle Biotechnology Co., Ltd.
See details and how to joinNCT07811622
Phase 2Taking people
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Where
Baoding, Changzhi, Chengde, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Jining, Kunming, Liuzhou, Pingdingshan, Siping, Tangshan, Tianjin, Wenzhou, Wuhan, Xian, Xiangyang, Yulin, Zhenzhou
Age
18 years to 75 years
People
60
Run by
Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07710248
Phase 4Taking people
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Where
Tianjin
Age
18 years to 75 years
People
38
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07788456
Phase 1/2Taking people
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
Where
Beijing, Bengbu, Nanchang, Tangshan, Tianjin, Xi’an, Zhengzhou
Age
18 years to 75 years
People
56
Run by
Jiangsu BioJeTay Biotechnology Co., Ltd.
See details and how to joinNCT06929299
Phase 2Not yet taking people in China
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Where
Tianjin
Age
18 years to 80 years
People
40
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687134
No phaseNot yet taking people in China
Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University People's Hospital
See details and how to joinNCT07662525
Phase 2/3Taking people
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Where
Beijing
Age
18 years to 65 years
People
164
Run by
Chinese SLE Treatment And Research Group
See details and how to joinNCT07657793
Phase 1Taking people
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Where
Suzhou
Age
16 years to 65 years
People
9
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07072247
Phase 1Taking people
IASO-782 in Autoimmune Hematological Diseases
Where
Tianjin, Wuhan
Age
18 years to 65 years
People
16
Run by
Shanghai IASO Biotechnology Co., Ltd
See details and how to joinNCT06534021
Phase 1Taking people
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
Where
Wuhan
Age
18 years and over
People
10
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07206758
No phaseTaking people
Romiplostim for Oral TPO-RA Resistant ITP
Where
Suzhou
Age
18 years and over
People
60
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07612319
Phase 1Not yet taking people in China
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
Where
Haidian
Age
18 years to 65 years
People
6
Run by
Jian Zhu
See details and how to joinNCT07599280
Phase 3Not yet taking people in China
ATRA for Management of Primary ITP
Where
Beijing
Age
18 years and over
People
192
Run by
Peking University People's Hospital
See details and how to joinNCT07597395
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Where
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan, Wuxi, Zhenjiang
Age
18 years and over
People
69 worldwide
Run by
argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00
Phase 3Taking people
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Where
Jinan
Age
18 years to 80 years
People
86
Run by
Shandong University
See details and how to joinNCT07559331
Phase 4Taking people
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Where
Tianjin
Age
18 years to 60 years
People
224
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04518475
Early phase 1Taking people
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
Where
Wuhan
Age
18 years to 75 years
People
27
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07441525
Early phase 1Not yet taking people in China
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
Where
Wuhan
Age
18 years to 75 years
People
27
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07416032
No phaseTaking people
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
6 years to 17 years
People
500
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06107582
Phase 2Taking people
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
18 years and over
People
160
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07234019
Phase 2Taking people
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
18 years and over
People
160
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07297563